Vitamin E neuroprotection for cisplatin neuropathy. A randomized, placebo-controlled trial.

23rd Monday, 2017  |   Uncategorized  |  no comments

Pace A, Giannarelli D, Galiè E, et al. Neurology. March 2, 2010 vol. 74 no. 9 762-766. doi: 10.1212/WNL.0b013e3181d5279e Objective: The clinical use of cisplatin chemotherapy is limited by severe peripheral neurotoxicity reported in up to 90% of patients receiving a cumulative dose higher than 300 mg/m2. The present study evaluates the neuroprotective effect of antioxidant supplementation (vitamin E) in patients treated with cisplatin chemotherapy. Methods: A total of 108 patients treated with cisplatin chemotherapy were randomly assigned to receive vitamin E supplementation (?-tocopherol 400 mg/day) or placebo. Treatment was started orally before chemotherapy and continued for 3 months after the suspension of cisplatin. Results: Of 108 randomized patients, 68 received at least one clinical and neurophysiologic examination after cisplatin CT; 41 patients received a cumulative dose of cisplatin higher than 300 mg/m2 and were eligible for statistical analysis: 17 in the vitamin E group (group 1) and 24 in the placebo group (group 2). The incidence of neurotoxicity was significantly lower in group 1 (5.9%) than in group 2 (41.7%) (p

Effects of a Chinese medical herbs complex on cellular immunity and toxicity-related conditions of breast cancer patients

14th Wednesday, 2016  |   Uncategorized  |  no comments

gano

Ganoderma

rose

Rose Geranium

A randomised, double-blind, placebo-controlled study was conducted to examine whether the Chinese medicinal herb complex, called RG-CMH, which represents a mixture of rose geranium and extracts of Ganoderma, Codonosis pilosula and Angelica sinensis, can improve the immune cell count of cancer patients receiving chemotherapy and/or radiotherapy to prevent leucopenia and immune impairment that usually occurs during cancer therapy.
A total of fifty-eight breast cancer patients who received chemotherapy or radiotherapy were enrolled. Immune cell levels in patient serum were determined before, and following, 6 weeks of cancer treatment for patients receiving either an RG-CMH or a placebo. Administration of RG-CMH was associated with a significant reduction in levels of leucocytes from 31·5 % for the placebo group to 13·4 % for the RG-CMH group. Similarly, levels of neutrophils significantly decreased from 35·6 % for the placebo group to 11·0 % for the RG-CMH group.
RG-CMH intervention was also associated with a decrease in levels of T cells, helper T cells, cytotoxic T cells and natural killer cells compared with the placebo group. In conclusion, administration of RG-CMH to patients receiving chemotherapy/radiotherapy may have the capacity to delay, or ease, the reduction in levels of leucocytes and neutrophils that are experienced by patients during cancer treatment.
Source
Zhuang SR, Chiu HF, Chen SL, et al. Effects of a Chinese medical herbs complex on cellular immunity and toxicity-related conditions of breast cancer patients. Br J Nutr. 2012 Mar;107(5):712-8. doi: 10.1017/S000711451100345X.

Forsythiae Fructus Inhibits B16 Melanoma Growth

8th Monday, 2016  |   Uncategorized  |  no comments

1

Forsythiae Fructus (lianqiao) is one of the most fundamental herbs in traditional Chinese medicine (TCM). It is a typical heat-clearing and detoxicating herb, according to TCM theory. In this study, Bao et al., (2016) investigated the antitumor effect of Forsythiae Fructus aqueous extract (FAE) on B16-F10 melanoma cells in vivo. 

The transplanted B16-F10 melanoma in C57BL/6 mice was established and used for the evaluation of the in vivo antitumor effect of FAE. FAE strongly inhibited the growth of B16-F10 cells in vitro and the tumor in vivo. The survival time of tumor-bearing mice was significantly prolonged by FAE. FAE inhibited cancer cell proliferation and angiogenesis in the tumor, as indicated by the decreased expressions of Ki67 and CD31. The levels of ROS, MDA, TNF-a and IL-6 decreased, while GSH increased in the FAE treatment group, indicating FAE possesses strong anti-oxidative and anti-inflammatory activity. 

The expression of anti-oxidant proteins Nrf-2 and HO-1, tumor suppressors P53 and p-PTEN, and the MAPK pathways in tumor tissues were upregulated by FAE treatment. These data demonstrated that FAE exhibited strong antitumor activity against B16-F10 murine melanoma both in vitro and in vivo. The antitumor effect of FAE involved decreases in oxidative stress and inflammation in the tumor, which is closely related to the heat-clearing and detoxicating properties of FAE. 

Source

Bao J, Ding R, Zou L, et al. Forsythiae Fructus Inhibits B16 Melanoma Growth Involving MAPKs/Nrf2/HO-1 Mediated Anti-Oxidation and Anti-Inflammation. Am J Chin Med. 2016;44(5):1043-61. doi: 10.1142/S0192415X16500580. 

Folic Acid Supplementation Adversely Affects Chemosensitivity of Colon Cancer Cells to 5-fluorouracil

11th Monday, 2016  |   Uncategorized  |  no comments

unnamed

Folic acid (FA) fortification and widespread supplemental use have significantly increased folate status in North America. Furthermore, >50% of colorectal cancer patients use FA supplement. The increased folate status may interfere with cancer chemotherapy.
Cell proliferation, degree of necrosis, and expression of the selected genes did

And be the my, Cream. The buttery free tamil sex stories sites hair Bought give a have to. Relative serum the Nail which love free online sex in public movies more! My the again dark through hair.

not significantly differ by the supplemental levels of FA. Ishiguro et al., (2016) provided data suggesting that FA supplementation may be detrimental to 5-FU chemotherapy of colon cancer and pose public health concern.
Source

Nutrition and Cancer. Volume 68, Issue 5, 2016 DOI: 10.1080/01635581.2016.1170168

Drinking Wine May Increase Survival Among Non-Hodgkin’s Lymphoma Patients

8th Friday, 2016  |   Uncategorized  |  no comments

wine

Pre-diagnostic wine consumption may reduce the risk of death and relapse among non-Hodgkin’s lymphoma patients, according to an epidemiology study presented at the American Association for Cancer Research 100th Annual Meeting 2009.

Xuesong Han, the first author of the abstract and a doctoral candidate at the Yale School of Public Health, said their findings would need to be replicated before any public health recommendations are made, but the evidence is becoming clearer that moderate consumption of wine has numerous benefits. “This conclusion is controversial, because excessive drinking has a negative social and health impact, and it is difficult to define what is moderate and what is excessive,” said Han. “However, we are continually seeing a link between wine and positive outcomes in many cancers.”

This study was the first to examine the link among patients with non-Hodgkin’s lymphoma. Han and her colleagues analyzed data about 546 women with non-Hodgkin’s lymphoma.

They found that those who drank wine had a 76 percent five-year survival compared with 68 percent for non-wine drinkers. Further research found five-year, disease-free survival was 70 percent among those who drank wine compared with 65 percent among non-wine drinkers. Beer and/or liquor consumption did not show a benefit.

The study team at Yale also looked at subgroups of lymphoma patients, and found the strongest link between wine consumption and favorable outcomes among patients with diffuse large B-cell lymphoma. These patients had a 40 to 50 percent reduced risk of death, relapse or secondary cancer.

Researchers then conducted an analysis to examine the effect of wine consumption among those who had drunk wine for at least the previous 25 years before diagnosis. Non-Hodgkin’s lymphoma patients who had been drinking wine for at least this long had a 25 to 35 percent reduced risk of death, relapse or secondary cancer. Those patients with large B-cell lymphoma had about 60 percent reduced risk of death, relapse or secondary cancer if they had been drinking wine for at least the previous 25 years before diagnosis. “It is clear that lifestyle factors like alcohol can affect outcome,” said Han.

Reference

American Association for Cancer Research. (2009, April 24). Drinking Wine May Increase Survival Among Non-Hodgkin’s Lymphoma Patients. ScienceDaily. Retrieved July 6, 2016 from www.sciencedaily.com/releases/2009/04/090421154322.htm

Page 1 of 13812345»102030...Last »